Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;31(4):403-410.
doi: 10.1097/CAD.0000000000000891.

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer

Affiliations

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer

Min Liu et al. Anticancer Drugs. 2020 Apr.

Abstract

Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2-6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and eight had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 and 221 days, respectively. There were five patients (13.15%) with grade 3/4 leukopenia, three patients (7.89%) with grade 3/4 neutropenia and one patient (2.63%) with grade 3/4 diarrhea. The combination of irinotecan plus raltitrexed was effective for pretreated ESCC patients. Further studies are needed to determine the optimal dose of the two drugs.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Percentage change from baseline in tumor size. Each bar represents one case (n = 38) and bars represent best response in dimension of target lesions.
Fig. 2
Fig. 2
Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) in all patients. The median PFS and OS were 105 and 221 days, respectively.
Fig. 3
Fig. 3
Subgroups analyses of survival between different groups. (a) Kaplan–Meier estimates of progression-free survival (PFS) in patients who previously received chemotherapy containing 5-fluorouracil (5-FU) or not. (b) Kaplan–Meier estimates of overall survival (OS) in patients who previously received chemotherapy containing 5-FU or not. (c) Kaplan–Meier estimates of PFS in patients who previously received chemotherapy or chemoradiotherapy. (d) Kaplan–Meier estimates of OS in patients who previously received chemotherapy or chemoradiotherapy. (e) Kaplan–Meier estimates of PFS in patients who previously received different lines of treatment. (f) Kaplan–Meier estimates of OS in patients who previously received different lines of treatment.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424 - PubMed
    1. Wang QL, Xie SH, Li WT, Lagergren J. Smoking cessation and risk of esophageal cancer by histological type: systematic review and meta-analysis. J Natl Cancer Inst. 2017; 109 - PubMed
    1. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010; 116:1446–1453 - PubMed
    1. Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2010; 5:122–128 - PubMed
    1. Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, et al. Phase II trial of 5-fluorouracil, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. Oncologist. 2019; 24:163–e76 - PMC - PubMed

Publication types

MeSH terms